Asthma is reported in 4% to 13% of persons older than 60 years. [1] [2] [3] [4] [5] Not only is asthma in the aged more prevalent than previously considered but also morbidity and mortality in this group are high, with 50% to 66% of all asthma-related deaths occurring in adults older than 65 years. 2, [6] [7] [8] [9] Although coexisting lung disease, 10 comorbidities, 11, 12 and undertreatment 2, 8 contribute to worse outcomes, the effect of aging on asthmarelated airway inflammation and its regulation is also a likely major factor in heightened morbidity. Because of increases in age of the worldwide population, the number of persons older than 60 years is projected to grow to 72 million by the year 2030, 13 and with this increase, so will the unmet needs of aged patients with asthma.
The limited data available on airway inflammation in aged adults with asthma suggest there are increased airway neutrophil number values. 14, 15 However, these studies have not considered the potential effects of ''inflamm-aging'' (ie, lowgrade basal systemic inflammation, such as increased IL-1b, IL-6, and TNF-a levels) that are often observed with aging 16 nor have they been conducted in inner-city subjects, a population with a higher asthma morbidity. 17, 18 Additionally, analyses have not correlated airway inflammation with clinical features of disease or appropriately controlled for inhaled corticosteroid (ICS) use, a factor that might influence airway cellularity. 19 Establishing the characteristics of airway inflammation in aged asthmatic patients is an important step toward a greater understanding of the high morbidity and mortality rates in this population and to begin to formulate more effective treatments.
To address these unanswered questions, we recruited aged and younger asthmatic patients from an inner-city population, defined their clinical characteristics, and obtained sputum samples to measure patterns of airway inflammation. Furthermore, control populations of age-matched subjects without asthma were included to more fully assess the age-independent effects of asthma. Thus our study design allowed us to evaluate 3 aspects of aging and airway inflammation: (1) the effect of aging on asthma (ie, aged vs younger patients with asthma), (2) the effect of asthma on aging (ie, aged patients with asthma vs aged control subjects), and (3) the effect of aging itself (ie, aged vs younger control subjects). 
METHODS

Patient population
Potential study participants were adults receiving medical care at a tertiary-care center in New York City and were eligible if they were between the ages of 21 and 40 years or 60 years or older, spoke English, and had mild, moderate, or severe persistent asthma, as defined according to the National Heart, Lung, and Blood Institute's Expert Panel on Asthma. 20 Subjects were classified with asthma based on the presence of current episodic respiratory symptoms in the preceding 12 months, a doctor's diagnosis of asthma, and evidence of past or present reversible airflow obstruction. Subjects were excluded if they had a physician's diagnosis of chronic obstructive lung disease or emphysema, restrictive lung disease, or other chronic respiratory illness; had a smoking history of 10 or more pack-years; had dementia; received immunosuppressive medications (excluding corticosteroids) in the past 12 months; or were pregnant or lactating. To limit confounding because of comorbidities, we excluded subjects who did not meet the eligibility criteria for immunogerontological studies, as defined in the SENIEUR protocol. 21 To adjust for potential age-related effects on airway inflammation, we recruited age-matched control subjects who met the same inclusion and exclusion criteria but did not have a history of past or current asthma.
The study protocol was approved by the institutional review board, and written informed consent was obtained from the participants before enrollment. Additional information, including subject recruitment, is provided in the Methods section in this article's Online Repository at www.jacionline.org.
Baseline assessment
Data were collected on sociodemographic characteristics, past asthma history, asthma morbidity over the 12 months before study enrollment, current asthma medications, comorbidities, and smoking history. Baseline level of asthma control was assessed with the Asthma Control Test (ACT), 22 and asthma-related quality of life was assessed with the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ). 23, 24 Lung function was performed in asthmatic patients and control subjects according to the standards specified by consensus guidelines. 25 Additional information is provided in the Methods section in this article's Online Repository.
Run-in period
Asthmatic patients entered a 2-week run-in period to measure ICS adherence and adjust for potential differences in sputum inflammatory cell counts secondary to corticosteroid use. During this time, ICS adherence was determined either by attaching a DOSER inhalations tracker (MediTrack, Hudson, Mass) to the inhaler or by recording the counter numbers on the patients' ICS at the run-in visit and again at sputum collection.
Sputum induction visit
Sputum induction and processing are described in the Methods section in this article's Online Repository at www.jacionline.org.
Multiplex for detection of inflammatory cytokine proteins
Sputum supernatants were assayed for a panel of T H 17 cytokines, eotaxin-1, TGF-b, and IL-8, as described in this article's Online Repository at www. jacionline.org.
Measurement of sputum regulatory T cells
To assess whether aging alters regulation of airway inflammation, we measured regulatory T (Treg) cells from the sputum using flow cytometry, as described in the Methods section in this article's Online Repository. Treg cells were reported as the percentage of CD3 1 CD4 1 cells expressing forkhead box P3 (Foxp3) and being CD127 low . 26 
Statistical analysis
Comparisons between groups are presented by using numbers (percentages), means (SDs), or medians (interquartile ranges) for skewed distributions. Comparison of cell counts, cytokine levels, baseline clinical characteristics, atopic sensitization, and past and present clinical features of asthma among aged versus younger asthmatic patients and aged versus younger control subjects was done by using x 2 tests, t tests, or Wilcoxon tests, as appropriate. We also conducted multiple regression analyses comparing sputum cell counts and cytokine levels among aged versus younger asthmatic patients and control subjects after controlling for medication adherence, ICS dose, years with asthma, atopy, race, sex, body mass index (BMI), and packyears of smoking.
We used linear or logistic regression (as appropriate) analyses to assess the adjusted relationship between sputum inflammatory markers (categorized as ''low'' vs ''high'' based on whether the level was less than or greater than the median) and asthma control and hospitalizations for asthma in the past 12 months among aged versus younger asthmatic patients. The model included an interaction term between age group and each marker to test whether specific cell types or cytokines have a differential effect on asthma control and odds ratios (ORs) for asthma hospitalizations according to age. Additional information is provided in the Methods section in this article's Online Repository.
RESULTS
Baseline characteristics of participants
The study sample consisted of 112 participants, including 35 aged and 37 younger asthmatic patients and 18 aged and 22 younger control subjects. Baseline characteristics of study participants according to age and asthma status are shown in Table I . Consistent with the epidemiology of an inner-city population, the cohort consisted predominantly of racial and ethnic minority groups. There were no significant differences in the distribution of sex, income, or education among aged versus younger asthmatic patients (P > .05 for all comparisons). Aged asthmatic patients were more likely to be non-Hispanic (P 5 .05) and insured by Medicare and Medicaid/Medicare (P < .01). Although the percentages of aged asthmatic patients who were allergen sensitized was high (74.3%), it was significantly lower than for younger patients (100%, P < .01). The distribution of allergens to which the aged and younger asthmatic patients were sensitized is shown in Table II . A higher comorbidity index score was seen in aged asthmatic patients (P < .01). There were no significant differences in the distribution of food allergies, eczema, rhinitis, or gastroesophageal reflux disease among aged versus younger asthmatic patients (P > .05 for all comparisons). There were no significant differences in the percentages of never smokers in aged compared with younger asthmatic patients (60.0% vs 78.4%, respectively; P 5 .15). The distribution of baseline characteristics was similar among aged versus younger control subjects, except for a higher comorbidity score (P < .01) and higher prevalence of gastroesophageal reflux disease (P 5 .01) among the former.
Past and present asthma history
Aged versus younger asthmatic patients had a significantly lower FEV 1 (69.1% vs 81.0%, respectively; P < .01; Table III) . Although all patients with asthma had prior evidence of reversibility of obstruction, as documented in their medical records, the mean change in milliliters of FEV 1 after bronchodilator therapy was significantly greater in the younger asthmatic patients (P 5 .03). Aged patients, on average, received their diagnosis at an older age than younger patients (P < .01) and had asthma for a greater duration (P < .01). In the past 12 months, no significant differences in the percentage of patients with a history of past intubation or the number of hospitalizations, urgent care visits, and exacerbations requiring oral or intravenous corticosteroids were observed among aged versus younger patients (P > .05 for all comparisons). Aged asthmatic patients had significantly worse asthma control, as measured by using the ACT (15.0 in the aged vs 18.0 in the young, P 5.01). There was not a significant difference in the overall effect of asthma on quality of life in the aged compared with the younger group (mini-AQLQ scores of 3.8 vs 4.4, respectively; P 5 .07). However, there was a statistically significant difference in the aged versus younger groups in the Asthma Quality of Life Questionnaire domains of Symptom and Activity Scores (3.7 vs 4.6 [P 5 .01] and 4.2 vs 5.0 [P 5 .05], respectively).
Most aged and younger patients with asthma were taking an ICS (74.3% vs 67.6%, P 5 .71). ICS dose was not significantly different between the 2 patient groups; most received medium to high doses.
Comparison of sputum inflammatory cell patterns between aged and younger patients with asthma
The total numbers of sputum cells were not significantly different among all 4 study groups (P 5 .75; Fig 1, A) . The total numbers of sputum neutrophils were significantly increased in aged (30.5 3 10 4 /mL) compared with younger asthmatic patients (13.0 3 10 4 /mL, P <.01; Fig 1, A) . Additionally, the percentage of sputum neutrophils was significantly increased in the aged asthmatic patients (23.1%) compared with younger patients (6.9%, P < .01) and age-matched control subjects (1.9%, P < .01; Fig  1, B) . However, no significance differences in total numbers (3.0 vs 7.0 3 10 4 /mL, respectively; P 5 .12) and percentages of sputum neutrophils (1.9% vs 3.5%, respectively; P 5 .20) were observed between aged and younger control subjects, suggesting that these changes are specific to asthma. After adjusting for ICS adherence, ICS dose, years with asthma, atopy, race, sex, BMI, and pack-years of smoking, the associations remained significant.
Similarly, absolute numbers and percentages of sputum eosinophils were significantly increased in the aged (7.0 3 10 4 /mL and 3.8%, respectively) compared with younger (2.0 3 10 4 /mL [P < .01] and 1.2% [P < .01], respectively) asthmatic patients and aged control subjects (1.0 3 10 4 /mL [P < .01] and 0.7% [P < .01], respectively). This increase was not secondary to aging, as suggested by the nonsignificant difference between eosinophil numbers (P 5 .69) and percentages (P 5 .85) in aged and younger control subjects. Analyses adjusting for ICS adherence, ICS dose, years with asthma, atopy, race, sex, BMI, and pack-years of smoking showed similar results.
Cytokine expression between older and younger patients with asthma
We measured protein expression of several cytokines, including some involved in recruitment of neutrophils (IL-8) common to ''inflamm-aging'' (IL-1b, IL-6, and TNF-a), T H 17 cells (IL-17A, IL-17F, IL-21, IL-23, IL-27, and macrophage inflammatory protein [MIP] 3a/CCL20), and eosinophils (IL-5 and eotaxin-1, Table IV ). Levels of sputum IL-5 (P 5 .02), IL-6 (P < .01), IL-8 (P 5 .01), IL-10 (P 5 .03), IL-17F (P 5 .03), eotaxin-1 (P 5 .02), and GM-CSF (P 5 .04) were significantly increased in aged asthmatic patients, suggesting an aging effect on asthma. Although IL-27 levels were higher in aged versus younger asthmatic patients (P 5 .06), the difference was not significant. To determine the effect of asthma on aging, we compared aged asthmatic patients with age-matched control subjects and found significantly increased sputum protein IL-6 (P 5 .01) and IL-10 (P 5 .02) levels and markers of T H 
Sputum Treg cell percentages
There were no significant differences in percentages of sputum Treg cells (expressed as CD3
1
CD4
1 lymphocytes expressing Foxp3 1 CD127 low ) between aged (10.7%) versus younger asthmatic patients (7.5%, P 5 .27), aged asthmatic patients versus aged control subjects (14.6%, P 5 .62), and aged versus younger control subjects (16.3%, P 5 .34; see Fig E2 , B, in this article's Online Repository at www.jacionline.org). However, the percentage of Treg cells was lower in younger asthmatic patients compared with those in age-matched control subjects (P 5 .02), suggesting that the percentages of Treg cells are decreased only in younger asthmatic patients compared with those in agedmatched control subjects. There was no statistical difference in the median fluorescence intensity (MFI) of Treg cells, a surrogate Data are presented as absolute numbers of subjects (percentages). Detectable IgE levels to antigen were determined either by means of skin prick testing or serum IgE measurement (described in the Methods section).
marker of Treg cell function, 27, 28 between aged and younger patients with asthma and between patients with asthma and agematched control subjects (see Table E1 in this article's Online Repository at www.jacionline.org).
Association between clinical characteristics of asthma and inflammatory markers
The mean difference in ACT scores among asthmatic patients with high versus low IL-6 levels in aged subjects was 24.5 units compared with 2.4 units among younger patients (P 5 .01), suggesting a differential relationship between IL-6 levels and asthma control according to age (Fig 2, A) . Similarly, aged versus younger patients with high versus low MIP-3a/CCL20 levels had an ACT score differences of 23.6 versus 2.3 units (P 5 .03), also suggesting an age-specific effect of this cytokine. No significant age-associated interactions between neutrophil and eosinophil percentages; IL-1b, IL-5, IL-8, IL-17A, IL-17F, IL-23, IL-27, and GM-CSF levels; and ACT scores were observed (P > .05 for all other comparisons; Fig 2, A, and see Table E2 in this article's Online Repository at www.jacionline.org).
The OR for asthma hospitalizations (over the past 12 months) of aged patients with high neutrophil percentages was 6.7 versus 0.1 in younger patients (P < .01 for interaction; Fig 2, B) .
Additionally, aged asthmatic patients with high sputum IL-1b, IL-6, and MIP-3a/CCL20 levels had increased ORs for hospitalization of 7.0, 60.0, and 28.0 versus 0.4 (P 5 .03), 2.5 (P 5 .05), and 0.7 (P 5 .01) in the younger patients. Conversely, no significant interaction between age group and hospitalization was observed for eosinophil percentage and IL-5, IL-8, IL-17A, IL-17F, IL-23, IL-27, and GM-CSF levels (P > .05 for all comparisons; Fig 2, B , and see Table E2 ).
DISCUSSION
Our study investigated the relationship of aging on airway inflammation in asthmatic patients, as measured in induced sputum, and its association with clinical outcomes, including disease control. We found that aged asthmatic patients have a different pattern of sputum inflammation, which is characterized by increases in both neutrophil and eosinophil values and increased protein expression of IL-1b, IL-6, IL-8, eotaxin-1, GM-CSF, and cytokines associated with T H 17 cells. These identified markers have potential clinical relevance. In patients older than 60 years, increased sputum IL-6 and MIP-3a/CCL20 levels were significantly associated with decreased asthma control, and increased sputum neutrophil values and IL-1b, IL-6, and MIP-3a/ CCL20 levels correlated to an increased risk of hospitalization in the past 12 months. Our findings suggest that selective age-related inflammatory markers have relationships to clinical features of asthma. Further research of these pathways might provide new management strategies for this vulnerable group of patients.
The limited data to define airway inflammation in aged adults suggest that this group of patients tends to have increased airway neutrophil values. [29] [30] [31] The sputum neutrophil values that we found in our groups of asthmatic patients are slightly less than in previous reports, [29] [30] [31] [32] but these differences might relate to methods of sputum collection, 33 ICS doses, or underlying severity of asthma. Nonetheless, our groups of younger and aged patients received comparable doses of ICSs, and no relationship was found between ICSs and sputum neutrophil values. Although previous studies provided an initial insight to features of airway inflammation in the aged, these reports did not match study populations for disease severity and intensity of treatment, 14, 15, 34, 35 did not specifically address the effect of aging on immune markers of inflammation, 34 or did not evaluate inner-city patients, a highly at-risk asthma population in the United States.
Aging is associated with several immune system changes, which might affect inflammation. 36 Increased concentrations of proinflammatory cytokines (eg, TNF-a and IL-6) in the absence of an underlying infection or systemic inflammatory disorder defines a process referred to as ''inflamm-aging'' 16 and is frequently observed in aged adults. In the lung the effect of ''inflamm-aging'' is reflected by an increase bronchoalveolar lavage fluid neutrophil values and IL-6 levels, even without obvious airway disease, 37, 38 and changes proposed to be secondary to increased systemic inflammation, which spills over into the airways. 39, 40 These age-related changes highlight the need to evaluate appropriate controls to differentiate age versus asthma-related variability. Although we did not find evidence of ''inflamm-aging'' in our aged control population, our data offer insights into how aging can affect inflammation in asthmatic patients. A key future step will be to identify and establish mechanisms leading to these changes, how they can affect the increased morbidity in this population, and seek age-specific treatments to potentially improve outcomes.
One interpretation of the findings in our population of aged asthmatic patients is that the ''inflamm-aging'' patterns were reflected in sputum samples by increased neutrophil values and levels of IL-6, IL-8, and cytokines associated with T H 17 cells. However, the lack of a significant difference in neutrophil values and levels of these cytokines among aged and younger control subjects suggests that these findings were not necessarily due to aging itself but rather occurred through asthma and aging.
There are intricate interactions between IL-6, IL-8, and T H 17 cells that might contribute to and explain age-related differences in sputum neutrophil values and are reflected in clinical outcomes, including diminished asthma control. For example, IL-6 differentiates naive T cells toward a T H 17 subset (rather than Treg cells) and increases the stability of committed T H 17 cells. [41] [42] [43] [44] [45] [46] [47] [48] [49] Conversely, neutralization of IL-6 in T-cell cocultures decreases T H 17 cell numbers, 50 and administration of anti-IL-6 to patients with rheumatoid arthritis significantly decreases peripheral T H 17 cell numbers. 44 IL-27 is a complex cytokine with both proinflammatory and anti-inflammatory properties, inhibiting the development of T H 17 from naive T cells but with limited effect on the stability of committed T H 17 cells. 51, 52 Furthermore, IL-27 has been reported to inhibit Treg cells. 51, 52 T H 17 cells promote neutrophilia through multiple mechanisms, 53, 54 including secretion of the neutrophil chemoattractant CXCL8 (IL-8), 55 and are associated with asthma in younger adults that is less responsive to ICSs.
56,57 Although we did not measure clinical responsiveness to ICSs in our asthmatic patients, aged patients, despite similar ICS treatments, had significantly decreased asthma control compared with younger patients, which was associated with increased levels of IL-6 and the T H 17 cytokine MIP-3a/CCL20. Furthermore, aged asthmatic patients with increased sputum neutrophil values and IL-1b, IL-6, and MIP-3a/CCL20 levels had a greater risk of hospitalization.
The significantly increased IL-6 levels in aged asthmatic patients is of particular interest and potential clinical relevance. For example, increased systemic levels of IL-6 are associated with increased frailty and higher morbidity of chronic diseases in the aged. [58] [59] [60] Of note, our population of aged control subjects did not have increased sputum IL-6 levels, which might be due to the fact that we measured IL-6 levels in sputum and not plasma. In younger patients variants of the IL-6 receptor, 61 polymorphisms of the IL-6 gene, 62 and increased sputum IL-6 levels are associated with more severe asthma. 63 Moreover, whether overexpression of IL-6 contributes to diminished corticosteroid responsiveness with aging has yet to be established.
We also found an increase in sputum eosinophil values in the aged asthmatic patients compared with the younger asthma population, which might reflect poorer asthma control in the latter group. Although increases in eosinophil values reflect disease severity, risks for exacerbations, and a T H 2 immune profile, our initial prejudice and that in the literature suggested that the dominant inflammatory cell would be the neutrophil in the aged group. However, allergen-sensitized and airwaychallenged aged mice had both increased airway eosinophil and neutrophil populations. 64, 65 A potential explanation for increased eosinophil values in aged asthmatic patients is a high frequency of allergic sensitization and increased eotaxin and IL-5 levels, all implying a T2 profile. In younger patients with asthma, combined increased airway neutrophil and eosinophil values often identify patients whose asthma is more difficult to control. 66 The persistence of sputum eosinophils in the aged asthmatic patients likely implies more severe disease, diminished responsive to ICSs, and a possible need for another approach (ie, biologics) to achieve greater disease control.
The function of Treg cells in asthmatic patients is not completely understood but has been proposed to suppress and regulate inflammation, including decreasing T H 17 cell numbers. 43, 67 Studies conducted in younger patients with asthma have shown that compared with age-matched control subjects, the numbers of peripheral and airway Treg cells are decreased, 68-71 a concept found in our younger patients. However, the role of Treg cells in aged patients with asthma has yet to be defined and has not been evaluated from airways samples. Most prior work suggests that Treg cell numbers increase with aging; however, the effect of aging on their function is less clear. [72] [73] [74] [75] The underlying mechanisms for increased Treg cell numbers with aging might include increased clonal expansion, in particular because of chronic viral infection (eg, cytomegalovirus), increased IL-15 protein and receptor expression (promoting Treg cell development and maintenance), and decreased expression of proapoptotic molecules. [76] [77] [78] . Association between sputum inflammation and asthma control and hospitalizations according to age group. Asthmatic patients were classified based on sputum cellular percentages and cytokine expression into high or low groups to evaluate the association between ACT scores (A) and ORs (B) for asthma hospitalization in the previous 12 months. Interaction is significant at a P value of less than .05.
One study has specifically analyzed markers of peripheral Treg cells in aged asthmatic patients and reported decreased numbers compared with those in healthy control subjects. 34 However, younger patients were not included for comparison. In our study we noted significantly decreased sputum IL-15 levels in the younger patients with asthma compared with those in agematched control subjects (Table IV) but no significant difference between aged asthmatic patients and control subjects. Although we did not find statistical differences between the Foxp3 MFI (as a marker of Treg cell function) of aged versus younger patients with asthma and between patients with asthma versus agedmatched control subjects, it might be that Treg cell suppressive activity is more accurately determined by coculture proliferation experiments.
Our study has several strengths and limitations that are worth acknowledging. The study population was from a single institution, thus limiting the generalization of our findings. However, our center is one of the largest providers of medical care to the East Harlem, New York, population, which has one of the highest rates of asthma in the United States. 79, 80 We recruited patients from an inner-city minority population, a group with increased morbidity and mortality. 81, 82 Previous studies of aged patients with asthma have not specifically addressed inner-city populations.
Our study is also strengthened by the comparison of agematched healthy control subjects and younger patients with asthma, which allowed us to examine the effect of asthma on aging, aging on asthma, and the effect of aging itself. Additionally, because higher ICS doses can increase sputum neutrophil values, 19 we included a run-in period to accurately measure and then control our analyses for ICS dose and adherence. We excluded subjects with a smoking history of greater than 10 pack-years to remove those with chronic obstructive pulmonary disease or possible asthma-chronic obstructive pulmonary disease overlap. 35 Limitations to our study include a 1-time sputum collection, and thus we could not evaluate the longitudinal stability of our findings. Additionally, by nature of their age, aged asthmatic patients had a longer duration of disease.
Our study of aged inner-city adults with asthma suggests that both aging and asthma affect airway inflammation. Establishing the characteristics of airway inflammation in aged adults and underlying mechanisms of these processes is an important first step in the development of age-specific or personalized therapy. Current treatment of asthma applies the pathophysiology and therapeutic principles of asthma largely based on work in younger patients to aged subjects. We believe that our study helps set the stage for further investigation on the role of aging, asthma, and airway inflammation in a high-risk group with significant unmet treatment needs.
We thank Dr Thomas Kraus for assistance with the Millipore cytokine analysis for this study.
Clinical implications: Sputum inflammation in asthmatic patients differs with increased age and is a pattern typically associated with decreased ICS response. These data might explain increased morbidity in aged asthmatic patients and supports identification of treatments directed toward inflammation in aged patients.
METHODS
Patient population
Potential participants were adults receiving medical care at a tertiary care center located in East Harlem, New York, from September 2013 to July 2015. Participants were eligible if they were between the ages of 21 and 40 years or 60 years or older, spoke English, and had mild, moderate, or severe persistent asthma, which was defined according to the National Heart, Lung, and Blood Institute's Expert Panel on Asthma. E1 We used an age cutoff of 60 years to define aged adults, which is consistent with prior studies of asthma in the aged E2-E4 and other studies investigating immunosenesence. E5 Subjects were classified as asthmatic based on the presence of current episodic respiratory symptoms in the preceding 12 months, a doctor's diagnosis of asthma, and evidence of past or present reversible airflow obstruction. Subjects were excluded if they had a physician's diagnosis of chronic obstructive lung disease or emphysema, restrictive lung disease, or other chronic respiratory illness; had a smoking history of 10 pack-years or more; had dementia; received immunosuppressive medications (excluding corticosteroids) in the past 12 months; or were pregnant or lactating.
To limit confounding because of comorbidities, we excluded subjects if they did not meet the eligibility criteria for immunogerontological studies, as defined in the SENIEUR protocol. E6 This included the presence of underlying inflammatory diseases (eg, collagen vascular disease or inflammatory bowel disease) and laboratory values (eg, erythrocyte sedimentary rate, comprehensive metabolic panel, and complete blood cell count) outside of an age-dependent reference range.
To adjust for potential age-related effects on airway inflammation, we recruited age-matched control subjects who met the same inclusion and exclusion criteria but did not have a history of past or current asthma. Potential patients with asthma and control subjects were recruited from the outpatient primary care and allergy clinics of Mount Sinai Hospital, which serve a large inner-city population. We identified potential patients and control subjects from queries of the clinic's registration system and/or based on referrals from the principal investigator or other study collaborators. Potential eligible patients and control subjects were offered participation in the study by the principal investigator or a research coordinator. Those who expressed an interest were invited to return for a study visit in which we explained the study and obtained written informed consent before enrollment. The study protocol was approved by the institutional review board.
Baseline assessment
Data were collected on sociodemographic characteristics, past asthma history (age of onset and history of endotracheal intubation), and asthma morbidity (use of systemic corticosteroids, emergency department visits, hospitalizations, and unscheduled urgent care visits for asthma) over the 12 months before enrollment, current asthma medications, comorbidities, and smoking history.
Subjects were classified as atopic if they had a detectable serum IgE level (>0.35 kIU/mL) or a positive skin test reaction (>3-mm wheal and positive histamine and negative saline controls) to at least 1 of the following antigens: house dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus), cockroach (Blattella germanica), mixed molds (Alternaria, Aspergillus, Penicillium, and Sphaerospermopsis species), cat, dog, tree mix, grass mix, ragweed, or weed mix.
Baseline level of control in patients with asthma was assessed with the ACT. E7 The ACT is a validated tool consisting of 5 questions assessing the frequency of shortness of breath, general asthma symptoms, use of rescue medications, effect of asthma on daily functioning, and overall self-assessment of asthma control, each on a 5-point scale. An ACT score of 20 or greater defined well-controlled asthma, a score of 16 to 19 defined not well-controlled asthma, and a score of 15 or less defined very poorly controlled asthma.
The Mini-AQLQ E8,E9 was used to measure asthma-related quality of life. The tool consists of 15 questions, each with a 7-point scale; both mean total score and scores for different domains (symptoms, activity limitation, emotional function, and environmental stimuli) were calculated.
Lung function was performed in both asthmatic patients and control subjects by using maximum expiratory flow volume, according to the standards specified by consensus guidelines. E10 Subjects withheld their short-acting bronchodilators for at least 6 hours before testing. Three reproducible measurements of FEV 1 and forced vital capacity were obtained before and 15 minutes after inhalation of albuterol (2.5 mg/3 mL) through a nebulizer. Significant reversibility was defined as a 12% or greater (and minimum of 200 mL) increase in postbronchodilator FEV 1 .
Run-in period
Patients with asthma entered a 2-week run-in period to measure adherence to ICSs and adjust for potential differences in sputum inflammatory cell counts secondary to corticosteroid use. During this time, adherence to ICSs was determined either by attaching a Smartdisc to the ICS inhaler or by recording the counter numbers on the patients' ICS at the run-in visit and again at the sputum collection visit. Asthma exacerbations during the run-in period were treated according to standard care.
E1
Sputum induction visit
Sputum was induced by adopting the methodology used by the National Heart, Lung, and Blood Institute-sponsored asthma networks and the Severe Asthma Research Program.
E11-E13 All participants performed baseline spirometry and then received 360 mg of short-acting bronchodilator (albuterol) before induction. Participants were excluded from sputum induction if their FEV 1 was less than 60% of predicted value. Subjects who had a respiratory tract infection or required a corticosteroid burst less than 4 weeks before the visit were rescheduled and required to have more than 4 weeks of asthma stability. Sputum was collected by using a 2-step collection method, which minimizes the contribution of saliva to samples, decreasing the percentages of squamous cells but potentially decreasing the neutrophil differential counts. E14 Subjects received nebulized hypertonic saline (3%) for a total of 12 minutes over three 4-minute intervals, a duration that does not significantly alter the granulocyte differential.
E12,E15 Sputum was processed by using the whole sputum method, adopting the protocol used by the Severe Asthma Research Program. E13 Because dithiothreitol (DTT) can disrupt cytokine protein levels, an aliquot of sputum was taken from all samples before processing. An equal amount of PBS was added to the aliquot to disperse the sputum, the sample was vortexed and spun down, and the supernatant was stored at 2808C, as previously done, and validated for reliability. E16,E17 The remainder of the sputum samples were weighed, DTT containing Sputolysin Reagent (Calbiochem, San Diego, Calif) was added (1 mL to 1 g of sample), the samples were placed in a 378C shaker for 15 minutes, and then they were washed with PBS. Cytospin preparations were prepared and stained with Diff-Quick (Dade Diagnostics of PR, Aguada, Puerto Rico) for differential cell counts. The sputum cell differential was determined by counting at least 500 white blood cells on the cytospin slides, excluding samples with a cell viability of less than 50% and greater than 20% squamous cells.
E11,E13 Based on these criteria, more than 80.0% of collected sputum samples were usable. All sputum samples were read by the same blinded reader (J.B.) to limit potential variability in slide interpretation and avoid bias in comparisons of younger versus aged subjects. Verification of the sputum cellular differentials was performed by a second independent and blinded investigator. There was not a significant difference between the 2 readings for all samples.
Multiplex for detection of inflammatory cytokine proteins
The sputum supernatant was assayed for a panel of cytokines by using a multiplex assay (Milliplex Human Th17 Magnetic Bead, Eotaxin-1, TGF-b, and IL-8; EMD Millipore, Billerica, Mass), according to the manufacturer's instructions. Briefly, samples, standards, and controls were added to the appropriate wells. The premixed magnetic beads were added to each well and incubated on a plate shaker for 16 to 18 hours at 48C. After washing, detection antibody was added and incubated on a plate shaker for 1 hour at room temperature, followed by streptavidin-phycoerythrin for 30 minutes. The plate was run on the Luminex 200 system (Luminex, Austin, Tex), and data were analyzed with Milliplex Analyst Software (EMD Millipore). In samples in which the cytokine concentration was less than the lower limit of detection provided by Millipore, it was not possible to determine whether the true cytokine expression was zero, and therefore the concentration was arbitrary assigned to be half the lower limit of detection.
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Measurement of sputum Treg cell numbers
To assess whether aging alters regulation of airway inflammation, we measured Treg cells from sputum by using flow cytometry, adapting previously published protocols.
E19,E20 A sample of the sputum cell pellet was resuspended in fluorescence-activated cell sorting buffer (PBS 1 1% BSA 1 2 mmol/L EDTA) with 5% mouse serum and transferred to fluorescence-activated cell sorting tubes. Cellular staining was performed with the antibodies of interest at 48C for 30 minutes. Treg cell subsets were examined by using mAbs to CD4 (Pacific Blue), CD3 (PerCP-Cy5), and CD127 (phycoerythrin), followed by intracellular staining for Foxp3 (fluorescein isothiocyanate) after fixing/permeabilizing cells overnight in Fixation/Permeabilization Working Solution from the Foxp3 Staining Buffer Set. All antibodies were purchased from eBioscience (San Diego, Calif). Samples were measured with an LSR II Flow Cytometer (BD Biosciences, San Jose, Calif), and data analysis was performed with FlowJo software (Tree Star, Ashland, Ore).
To address potential contamination with cellular debris from sputum samples and nonspecific staining with increased autofluorescence, we established the following recommended controls. E21 First, we performed analysis of samples with a viability of greater than 50% E21 to minimize dead cells in each sample. Second, we eliminated samples having greater than 20% squamous cells. Third, sputum samples were placed on ice immediately after collection and processed within 2 hours. Fourth, staining was performed with standard operating procedures, including staining on ice to reduce background staining and running isotype controls with each experiment. Fifth, gating for each experiment was based on within-experiment isotype controls. Sixth, compensation for spillover and spectral overlap was set before measurement with BD CompBeads. Seventh, compensation settings were maintained through the study. Finally, to minimize the contact of cells with DTT (which can affect cell viability and surface marker expression), samples were washed immediately with PBS after incubation. Treg cells were marked by CD3
1
CD4
1 cells expressing Foxp3 and CD127 low . E22 The frequency of true-positive cells was determined by subtracting the value of the isotype control from the value of the sample. A sample gating analysis is shown in Fig E2. We measured the MFI of Foxp3 because its expression has been positively correlated with Treg cell function.
E23,E24
Statistical analysis
Comparisons between groups are presented by using numbers (percentages), means (SDs), or medians (interquartile ranges) for skewed distributions. Comparison of cell counts, cytokine levels, baseline clinical characteristics, atopic sensitization, and past and present clinical features of asthma among aged versus younger asthmatic patients and aged versus younger control subjects was done by using x 2 tests, t tests, or Wilcoxon tests, as appropriate. We also conducted multiple regression analyses comparing sputum cell counts and cytokine levels among aged versus younger patients with asthma and control subjects while adjusting for medication adherence, ICS dose, years with asthma, atopy, race, sex, BMI, and smoking. All sputum data were included for analysis, regardless of whether the subjects were receiving treatment with an ICS. Power calculations were based on preliminary data collected before initiation of the study from sputum induction of 5 aged and 7 younger patients with asthma. From these data, we calculated that 28 subjects per group would provide a 90% power to detect a 1 SD or greater difference in IL-6 levels between groups at the .01 significance level.
To assess the relationship between sputum cell types, cytokines, and asthma control (ACT scores), we used linear regression analyses limited to patients with asthma. The model included a main term for age group (aged vs younger), a dichotomous indicator for each sputum inflammatory marker (eg, cell type or cytokine), and an interaction between them. Subjects were categorized as ''low'' or ''high'' based on whether the specific inflammatory marker was less than or greater than the median. In these models a significant interaction term indicated a differential effect of a cell type or cytokine on ACT scores for aged versus younger patients with asthma. Similarly, we fitted similar logistic regression models, assessing the relationship between cell types or cytokines and asthma hospitalizations. All models were adjusted for medication adherence and smoking history. A P value of less than .05 was considered statistically significant. All data management and statistical analyses were performed with SAS statistical software version 9.3 (SAS Institute, Cary, NC) and the R system for statistical computing, version 3. Values are expressed as medians (interquartile ranges).
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